ECSP13012541A - Combinaciones farmacéuticas - Google Patents
Combinaciones farmacéuticasInfo
- Publication number
- ECSP13012541A ECSP13012541A ECSP13012541A ECSP13012541A EC SP13012541 A ECSP13012541 A EC SP13012541A EC SP13012541 A ECSP13012541 A EC SP13012541A EC SP13012541 A ECSP13012541 A EC SP13012541A
- Authority
- EC
- Ecuador
- Prior art keywords
- combination
- mtor
- treatment
- kinase
- proliferative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
La presente invención, se refiere a una combinación farmacéutica que comprende: (a) un inhibidor catalítico de mTor, tal como una cinasa de fosfatidil-inositol-3 catalítica (PI3K), y un compuesto inhibidor de mTor, el cual es un derivado de imidazo-quinolina, y (b) cuando menos un compuesto aloestérico inhibidor de mTor, y opcionalmente, cuando menos un vehículo farmacéutica-mente aceptable, para su uso simultáneo, separado, o en secuencia, en particular para el tratamiento de las enfermedades proliferativas dependientes de cinasa del objetivo de mamífero de rapamicina (mTOR); y a los usos de esta combinación en el tratamiento de las enfermedades proliferativas dependientes de la cinasa mTor; a una composición farmacéutica, la cual comprende dicha combinación; al uso de esta combinación para la preparación de un medicamento para el tratamiento de una enfermedad proliferativa; a un paquete o producto comercial que comprende esta combinación como una preparación combinada, para su uso simultáneo, separado, o en secuencia; y a un método para el tratamiento de un animal de sangre caliente, en especial de un ser humano.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38944510P | 2010-10-04 | 2010-10-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP13012541A true ECSP13012541A (es) | 2013-06-28 |
Family
ID=44802399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP13012541 ECSP13012541A (es) | 2010-10-04 | 2013-04-01 | Combinaciones farmacéuticas |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20130178479A1 (es) |
| EP (1) | EP2624831A1 (es) |
| JP (1) | JP2013538876A (es) |
| KR (1) | KR20130108330A (es) |
| CN (1) | CN103153305A (es) |
| AR (1) | AR083267A1 (es) |
| AU (1) | AU2011312372A1 (es) |
| BR (1) | BR112013008074A2 (es) |
| CA (1) | CA2812786A1 (es) |
| CL (1) | CL2013000895A1 (es) |
| CO (1) | CO6710908A2 (es) |
| EC (1) | ECSP13012541A (es) |
| MA (1) | MA34554B1 (es) |
| MX (1) | MX2013003833A (es) |
| NZ (1) | NZ608375A (es) |
| PE (1) | PE20140203A1 (es) |
| PH (1) | PH12013500581A1 (es) |
| RU (1) | RU2013120357A (es) |
| SG (1) | SG188521A1 (es) |
| TW (1) | TW201217374A (es) |
| WO (1) | WO2012047775A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2825605C (en) | 2011-01-31 | 2019-05-07 | Novartis Ag | Heterocyclic derivatives |
| EP2675450B1 (en) * | 2011-02-16 | 2016-02-10 | Novartis AG | Combinations of therapeutic agents for use in the treatment of neurodegenerative diseases |
| WO2013192367A1 (en) * | 2012-06-22 | 2013-12-27 | Novartis Ag | Neuroendocrine tumor treatment |
| AU2013302702A1 (en) * | 2012-08-16 | 2015-02-19 | Novartis Ag | Combination of Pl3K inhibitor and c-Met inhibitor |
| JO3377B1 (ar) * | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
| EP3297629A1 (en) | 2015-05-20 | 2018-03-28 | Novartis AG | Pharmaceutical combination of everolimus with dactolisib |
| GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| BR112019010470A2 (pt) | 2016-11-23 | 2019-09-10 | Novartis Ag | métodos de realce de resposta imune com everolimo, dactolisib ou ambos |
| US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0510390D0 (en) * | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| CN102579467A (zh) * | 2005-11-14 | 2012-07-18 | 阿里亚德医药股份有限公司 | 雷帕霉素衍生物在治疗癌症中的用途 |
| RU2478387C2 (ru) * | 2007-02-20 | 2013-04-10 | Новартис Аг | ИМИДАЗОХИНОЛИНЫ В КАЧЕСТВЕ ДВОЙНЫХ ИНГИБИТОРОВ ЛИПИДКИНАЗЫ И mTOR |
-
2011
- 2011-09-30 AR ARP110103630A patent/AR083267A1/es unknown
- 2011-10-03 SG SG2013018254A patent/SG188521A1/en unknown
- 2011-10-03 CN CN201180048544XA patent/CN103153305A/zh active Pending
- 2011-10-03 RU RU2013120357/15A patent/RU2013120357A/ru not_active Application Discontinuation
- 2011-10-03 PE PE2013000776A patent/PE20140203A1/es not_active Application Discontinuation
- 2011-10-03 BR BR112013008074A patent/BR112013008074A2/pt not_active Application Discontinuation
- 2011-10-03 PH PH1/2013/500581A patent/PH12013500581A1/en unknown
- 2011-10-03 EP EP11770611.9A patent/EP2624831A1/en not_active Withdrawn
- 2011-10-03 AU AU2011312372A patent/AU2011312372A1/en not_active Abandoned
- 2011-10-03 MX MX2013003833A patent/MX2013003833A/es unknown
- 2011-10-03 US US13/876,021 patent/US20130178479A1/en not_active Abandoned
- 2011-10-03 CA CA2812786A patent/CA2812786A1/en not_active Abandoned
- 2011-10-03 KR KR1020137008528A patent/KR20130108330A/ko not_active Withdrawn
- 2011-10-03 TW TW100135797A patent/TW201217374A/zh unknown
- 2011-10-03 NZ NZ608375A patent/NZ608375A/en not_active IP Right Cessation
- 2011-10-03 WO PCT/US2011/054536 patent/WO2012047775A1/en not_active Ceased
- 2011-10-03 MA MA35783A patent/MA34554B1/fr unknown
- 2011-10-03 JP JP2013532854A patent/JP2013538876A/ja active Pending
-
2013
- 2013-04-01 EC ECSP13012541 patent/ECSP13012541A/es unknown
- 2013-04-03 CL CL2013000895A patent/CL2013000895A1/es unknown
- 2013-04-08 CO CO13090543A patent/CO6710908A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW201217374A (en) | 2012-05-01 |
| AU2011312372A1 (en) | 2013-04-04 |
| CL2013000895A1 (es) | 2013-09-27 |
| US20130178479A1 (en) | 2013-07-11 |
| SG188521A1 (en) | 2013-04-30 |
| CA2812786A1 (en) | 2012-04-12 |
| JP2013538876A (ja) | 2013-10-17 |
| AR083267A1 (es) | 2013-02-13 |
| EP2624831A1 (en) | 2013-08-14 |
| NZ608375A (en) | 2014-08-29 |
| CO6710908A2 (es) | 2013-07-15 |
| RU2013120357A (ru) | 2014-11-20 |
| PE20140203A1 (es) | 2014-02-28 |
| MX2013003833A (es) | 2013-06-28 |
| PH12013500581A1 (en) | 2013-05-20 |
| MA34554B1 (fr) | 2013-09-02 |
| WO2012047775A1 (en) | 2012-04-12 |
| KR20130108330A (ko) | 2013-10-02 |
| CN103153305A (zh) | 2013-06-12 |
| BR112013008074A2 (pt) | 2016-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6710908A2 (es) | Formulaciones farmacéuticas que comprenden inhibidores de p13k y de mtor, útiles en el tratamiento de enfermedades proliferativas | |
| CO6382119A2 (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
| AR122743A2 (es) | Composición farmacéutica de antagonistas de unión al eje pd-1 e inhibidores de mek | |
| CO6390066A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| SV2010003451A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| DOP2010000012A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k | |
| MX2019010354A (es) | Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo. | |
| ECSP15008695A (es) | Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa | |
| ECSP077324A (es) | Amidas bicíclicas como inhibidores de cinasa | |
| UY33286A (es) | Derivados de triazina disustituidos farmaceuticamente activos | |
| UY30559A1 (es) | Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
| BR112014018910A8 (pt) | Produto farmacêutico , kit, uso de vemurafenibe, produtos, métodos, composições e usos inovadores | |
| CL2013001093A1 (es) | Compuestos triciclicos inhibidores de la quinasa pi3 (pi3k); composicion farmaceutica que los comprende; metodo para tratar el cancer; y su uso para el tratamiento del cancer . | |
| CL2013003227A1 (es) | “compuestos derivados de indazol sustituidos, moduladores de la actividad de proteínas quinasas; proceso de obtención de ellos; método in vitro para inhibir proteínas quinasas; composición y combinación farmacéutica que los comprende; y su uso en el tratamiento del cáncer" pct | |
| AR091876A1 (es) | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas | |
| ECSP12011834A (es) | Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, métodos para su tratamiento y sus usos. | |
| MX2009008486A (es) | Imidazoquinolinas como inhibidores dobles de cinasa de lipido y mtor. | |
| CL2009000241A1 (es) | Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer. | |
| CU20140037A7 (es) | Derivados de estra- 1,3,5(10), 16- tetraen- 3- carboximida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
| ECSP13012994A (es) | COMBINACIÓN DE UN INHIBIDOR DE CINASA DE FOSFATIDIL-INOSITOL-3 (PI3K) Y UN INHIBIDOR DE mTOR | |
| CL2007000781A1 (es) | Nanoparticulas que comprenden un inhibidor de quinasa de tirosina receptora del factor de crecimiento derivado de plaquetas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades vasculares, tales como restenosis | |
| UY32829A (es) | Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo | |
| CL2013000021A1 (es) | Forma cristalina delta de la sal de arginina de perindoprilo; procedimiento de preparacion; composiciones farmaceuticas que la contienen; y su uso par el tratamiento de las enfermedades cardiovasculares, tales como hipertension arterial, insuficiencia cardiaca o enfermedad coronaria estable. | |
| AR081024A1 (es) | Asociacion de los inhibidores de la xantina oxidasa y la metformina y su uso | |
| BR112013025410A2 (pt) | tratamento terapêutico |